Prostate Cancer Treatment: How Doctors Choose Between Surveillance, Surgery and Radiation

A diagnosis of localized prostate cancer does not automatically mean surgery or radiation.

For some men, the recommended approach may be active surveillance. For others, doctors may recommend definitive treatment with surgery or radiation. The choice depends on factors including the cancer’s risk level, tumor characteristics, life expectancy, overall health and the patient’s priorities.

The key question is not simply, “Which treatment is best?” It is “Which approach makes sense for this cancer and this patient?”

First: How risky is the cancer?

Doctors generally consider factors such as PSA levels, biopsy results, tumor grade and stage when determining prostate cancer risk.

For men with low-risk disease, the American Urological Association and American Society for Radiation Oncology recommend active surveillance as the preferred management option. For favorable intermediate-risk disease, guidelines recommend discussing active surveillance, radiation therapy and radical prostatectomy.

That distinction matters because a cancer that is unlikely to cause harm for many years can be managed very differently from a cancer that is more likely to grow or spread.

Active surveillance: When treatment can wait

Active surveillance is not the same as ignoring prostate cancer.

It means closely monitoring the cancer and beginning treatment if tests indicate that it is becoming more aggressive. Monitoring can include PSA blood tests, examinations, imaging such as MRI and periodic biopsies.

The goal is to avoid or delay treatment-related side effects when immediate treatment is unlikely to provide enough additional benefit.

That can be important because treatments such as surgery and radiation can affect urinary, sexual and, in some cases, bowel function.

Active surveillance is particularly established for men with low-risk disease. For some favorable intermediate-risk patients, it may also be considered, although the risk of disease progression is higher than with low-risk cancer.

Surgery: Removing the prostate

Radical prostatectomy removes the prostate and surrounding tissue and is an established treatment for selected men whose cancer is confined to the prostate.

The operation can be performed through minimally invasive techniques, including robot-assisted laparoscopic surgery.

The potential advantage is that the known prostate tumor is removed. But surgery also has potential consequences, particularly urinary incontinence and erectile dysfunction.

The decision therefore involves more than whether a tumor can technically be removed. A patient’s cancer characteristics, health, life expectancy and preferences all matter.

Guidelines also emphasize that surgical decisions should take into account whether nerve-sparing is oncologically appropriate for the individual patient.

Radiation: Treating the cancer without removing the prostate

Radiation is another established definitive treatment for localized prostate cancer.

External-beam radiation therapy uses precisely targeted radiation delivered from outside the body. Brachytherapy uses radioactive sources placed in or near the prostate. The specific approach depends on the cancer and the treatment plan.

Modern radiation techniques are designed to target the prostate while limiting exposure to surrounding tissue. Treatment schedules can also vary, including shorter courses for some patients.

Radiation has its own potential side effects, including urinary, bowel and sexual problems. Those effects can differ from the effects experienced after surgery and can develop on different timelines.

That is why comparing treatments simply as “better” or “worse” can be misleading. The more useful question is what tradeoffs each approach presents for a particular patient.

What changes when the cancer is higher-risk?

The treatment conversation becomes more complicated when prostate cancer is high-risk or has spread beyond the prostate.

Depending on the stage and characteristics of the cancer, treatment can involve radiation combined with hormone therapy, androgen-deprivation therapy, chemotherapy, targeted treatments or other systemic approaches.

These treatments are not interchangeable, and the appropriate combination depends on the disease.

That is also why a treatment plan for localized low-risk cancer should not be used as a template for someone with advanced or metastatic disease.

The California access question

Treatment decisions are only part of the challenge.

A man may have several medically appropriate options but still face barriers to receiving them, including lack of insurance, cost, difficulty finding specialists or delays navigating the health care system.

That issue remains relevant in California. UCLA Health reported in September 2026 that California’s IMPACT program has provided prostate cancer treatment to more than 2,300 men over its 25-year history, focusing on uninsured and underinsured Californians who might otherwise struggle to obtain care. The program works with more than 600 health care providers and organizations statewide.

UCLA also reported that California has a prostate cancer incidence rate about 13% lower than the national rate but a mortality rate about 6% higher, citing American Cancer Society data.

For patients, access can therefore become part of the treatment equation.

Questions to ask before choosing a treatment

A prostate cancer diagnosis can make the decision feel urgent, but patients can ask their medical team to explain the choices in practical terms.

Questions can include:

• What is my prostate cancer risk group?
• Is active surveillance appropriate for me?
• If I choose surveillance, how often will I need testing or biopsy?
• What are the potential urinary effects of surgery?
• What are the potential sexual effects?
• What bowel or urinary effects could radiation cause?
• How might my age and other health conditions affect the decision?
• Should I get a second opinion?
• What happens if the cancer shows signs of progression?
• What treatment and financial assistance programs are available to me?

There is no universal treatment choice for localized prostate cancer.

For some men, the safest path may be monitoring rather than immediate treatment. For others, surgery or radiation may be appropriate. The important distinction is that these choices depend on the risk of the cancer, the patient’s health and life expectancy, and the tradeoffs the patient is willing to accept.

Understanding those differences can help patients have a more informed conversation with their urologist, radiation oncologist and broader cancer-care team.